SinoMab prices Hong Kong IPO low
Biopharmaceutical firm SinoMab BioScience has priced its Hong Kong listing at the bottom of guidance to raise HK$1.4bn ($178.6m), finding support from global long-only funds on the last day of bookbuilding.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: